Analyst firms · Citigroup · EVH
Citigroup EVH price target and rating history
Evolent Health Inc (EVH) · Consumer Discretionary
Citigroup rates Evolent Health Inc (EVH) Buy with a $6 price target, as of its latest action on Aug 11, 2026. It has published 3 rating actions on EVH since April 2024, including 1 upgrade and 1 downgrade. Across 4 firms with a EVH price target in the last 12 months, the median target is $7. Citigroup's $6 is 14% below that.
- Current rating
- Buy
- Price target
- $6
- Median target, all firms
- $7
- Actions on EVH
- 3
Citigroup price target on EVH
Every Citigroup rating on EVH
- Aug 11, 2026
- Jul 23, 2026
- Apr 22, 2024
How other firms rate EVH
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $6 | Aug 11, 2026 |
| Truist Securities | Hold | $7 | Jun 30, 2026 |
| KeyBanc Capital Markets | Sector Weight | Feb 25, 2026 | |
| Stephens | Overweight | $7 | Nov 13, 2025 |
| BMO Capital Markets | Outperform | $7 | Nov 13, 2025 |
Questions about Citigroup and EVH
- What is Citigroup's price target for EVH?
- Citigroup's latest stated price target for Evolent Health Inc (EVH) is $6, from its action on Aug 11, 2026.
- What is Citigroup's rating on EVH?
- Citigroup rates EVH Buy, a bullish rating, as of Aug 11, 2026.
- When did Citigroup last change its view on EVH?
- On Aug 11, 2026, Citigroup upgrades to Buy from Neutral, price target $6.
- How does Citigroup's EVH target compare with other analysts?
- Across 4 firms with a EVH price target in the last 12 months, the median target is $7. Citigroup's $6 is 14% below that.
More EVH rating histories
All Citigroup ratingsEVH news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.